Bandaríkin - enska - NLM (National Library of Medicine)

maia pharmaceuticals, inc. - levothyroxine sodium anhydrous (unii: 054i36cpmn) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium for injection is indicated for the treatment of myxedema coma. important limitations of use: the relative bioavailability between levothyroxine sodium for injection and oral levothyroxine products has not been established.  caution should be used when switching patients from oral levothyroxine products to levothyroxine sodium for injection as accurate dosing conversion has not been studied. none. pregnancy category a – there are no reported cases of levothyroxine sodium for injection used to treat myxedema coma in patients who were pregnant or lactating.  studies in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not shown an increased risk of fetal abnormalities.  therefore, pregnant patients who develop myxedema should be treated with levothyroxine sodium for injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus. patients in labor who develop myxedema hav

Bandaríkin - enska - NLM (National Library of Medicine)

st marys medical park pharmacy - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium is used for the following indications: hypothyroidism - as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. pituitary tsh suppression - in the treatment or prevention of various types of euthyroid goiters (see warnings and precautions ), including thyroid nodules (see warnings and precautions ), subacute or chronic iymphocytic thyroiditis (hashimoto's thyroiditis), multinodular goiter (see warnings and precautions ), and, as an adjunct to surgery and radioiodine therapy in the managem

Bandaríkin - enska - NLM (National Library of Medicine)

northwind pharmaceuticals - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 0.1 mg - levothyroxine sodium is used for the following indications: hypothyroidism – as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. pituitary tsh suppression – in the treatment or prevention of various types of euthyroid goiters (see warnings and precautions), including thyroid nodules (see warnings and precautions), subacute or chronic lymphocytic thyroiditis (hashimoto’s thyroiditis), multinodular goiter (see warnings and precautions) and, as an adjunct to surgery and radioiodine therapy in the management of thyr

Bandaríkin - enska - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - hypothyroidism: levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression:  levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency [see warnings and precautions (5.3)] . experience with levothyroxine use in pregnant women, including data from post-marketing studies, have not reported increased rates of major birth defects or miscarriages [see data]. there are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. since tsh levels may increase during pregnancy, tsh should be monitored and levothyroxine sodium tablets dosage adjusted during pregnancy [see cli

Bandaríkin - enska - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - hypothyroidism: levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression:  levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency [see warnings and precautions (5.3)] . experience with levothyroxine use in pregnant women, including data from post-marketing studies, have not reported increased rates of major birth defects or miscarriages [see data]. there are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. since tsh levels may increase during pregnancy, tsh should be monitored and levothyroxine sodium tablets dosage adjusted during pregnancy [see cli

Bandaríkin - enska - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - hypothyroidism levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: • levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see warnings and precautions (5.4)]. • levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. levothyroxine sodium tablets is contraindicated in patients with uncorrected adrenal insufficiency [see warnings and precaution

Bandaríkin - enska - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - hypothyroidism: levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression:  levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency [see warnings and precautions (5.3)] . experience with levothyroxine use in pregnant women, including data from post-marketing studies, have not reported increased rates of major birth defects or miscarriages [see data]. there are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. since tsh levels may increase during pregnancy, tsh should be monitored and levothyroxine sodium tablets dosage adjusted during pregnancy [see cli

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.1 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.1 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - levothyroxine sodium, quantity: 0.2 mg - tablet, uncoated - excipient ingredients: maize starch; gelatin; croscarmellose sodium; magnesium stearate; lactose monohydrate - indicated for the management of demonstrated thyroid hormone deficiency. and also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.